Cancer Treatment Reviews
Volume 26, Issue 1 , Pages 11-27 , February 2000

Tumour progression and angiogenesis in bone metastasis from breast cancer: new approaches to an old problem

References 

    REFERENCES
  1. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61–66
  2. Kamby C, Rasmussen BB, Kristensen B. Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer. 1989;60:252–257
  3. Elte JWF, Bijvoet OLM, Cleton FJ, van Oosterom AT, Sleeboom HP. Osteolytic metastases in breast carcinoma. Pathogenesis, morbidity and bisphosphonate treatment. Eur J Cancer Clin Oncol. 1986;22:493–500
  4. Front D, Schneck SO, Frankel A, Robinson E. Bone metastases and bone pain in breast cancer. JAMA. 1979;242:1747–1748
  5. Twycross RG, Fairfield S. Pain in far-advanced cancer. Pain. 1982;14:102–110
  6. Paterson AHG. Bone metastases in breast cancer, prostate cancer and myeloma. Bone. 1987;8:S17–S22
  7. Orr FW, Sanchez-Sweatman OH, Kostenuik P, Singh G. Tumor-bone interactions in skeletal metastasis. Clin Ortop Rel Res. 1995;312:19–33
  8. Yoneda T, Sasaki A, Mundy GR. Osteolytic bone disease in breast cancer. Breast Cancer Res Treat. 1994;32:73–84
  9. Garrett IR. Bone destruction in cancer. Semin in Oncol. 1993;20:4–9
  10. Stetler-Stevenson, W. G. Corcoran, M. L. Tumor angiogenesis: Functional similarities with tumor invasion, Goldberg, I. D.Rosen, E. M. Regulation of Angiogenesis, Birkhäuser Verlag/Basel, Switzerland, 1997, 413, 418
  11. Miyaska M. Cancer Metastasis and Adhesion Molecules. Clin Orthop Rel Res. 1995;312:10–18
  12. Engels, K. Fox, S. B. Harris, A. L. Angiogenesis as a biologic and prognostic indicator in human breast carcinoma. Goldberg, I. D.Rosen, E. M. Regulation of Angiogenesis, Birkhäuser Verlag/Basel, Switzerland, 1997, 113, 156
  13. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–364
  14. Juliano RL. The role of β1integrins in tumors. Sem in Cancer Biol. 1993;4:277–283
  15. Bernstein LR, Liotta LA. Molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis. Curr Opinion in Oncol. 1994;6:106–113
  16. Albelda SM. Biology of Disease: Role of integrins and other cell adhesion molecules in tumour progression and metastasis. Lab Invest. 1993;68:4–17
  17. Maemura M, Dickson RB. Are cellular adhesion molecules involved in the metastasis of breast cancer?. Breast Cancer Res Treat. 1994;32:239–260
  18. Varner JA, Cheresh DA. Integrins and cancer. Curr Opin Cell Biol. 1996;8:724–730
  19. Maemura M, Dickson RB. Are cellular adhesion molecules involved in the metastasis of breast cancer?. Breast Cancer Res Treat. 1994;32:239–260
  20. Lochter A, Bissell MJ. Involvement of extracellular matrix constituents in breast cancer. Sem in Cancer Biol. 1995;6:165–173
  21. Paget S. The distribution of secondary growths in cancer of the breast. Lancet. 1889;1:571–572
  22. Arguello F, Baggs RB, Frantz CN. A murine model of experimental metastasis to bone and bone marrow. Cancer Res. 1988;48:6876–6881
  23. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 1995;55:3551–3557
  24. Wu TT, Sikes RA, Cui Q, Thalmann GN, Kao C, Murphy CF, et al. Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int J Cancer. 1998;77:887–894
  25. Batson OV. The role of vertebral veins in metsatic processes. Ann Intern Med. 1942;16:38–46
  26. Geldolf AA, Rao BR. Factors in prostate cancer metastasis. Anticancer Res. 1990;10:1303–1306
  27. Harada M, Shimizu A, Nakamura Y, Nemotot R. Role of the vertebral venous system in metasatic spread of cancer to bone. Adv Exp Med Biol. 1992;324:83–92
  28. Shevrin DH, Gorny KI, Kukreja SC. Patterns of metastasis by the human prostate cancer cell line PC-3 in athymic nude mice. Prostate. 1989;15:187–194
  29. Ewing J. Treatise on Tumors. Philadelphia USA: WB Saunders; 1928;
  30. Mohle R, Bautz F, Rafii S, Moore MA, Brugger W, Kanz L. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood. 1998;91:4523–4530
  31. Cecchini MG, Ball R, Gautschi E, Miescher S, Wetterwald A, Zimmermann R, et al. Identification of a bone marrow endothelium homing peptide by phage peptide library panning in vivo. J Bone Miner Res. 1997;S
  32. Guise TA, Mundy GR. Cancer and Bone. Endocrine Reviews. 1998;19:18–54
  33. Orr FW, Varani J, Gondek MD, Ward PA, Mundy GR. Chemotactic responses of tumor cells to products of resorbing bone. Science. 1979;203:176–179
  34. Kostenuik PJ, Singh G, Suyama KL, Orr FW. Stimulation of bone resorption results in a selective increase in growth rate of spontaneously metastatic Walker 256 cancer cells in bone. Clin Exp Metastasis. 1992;10:411–418
  35. Manishen WJ, Sivananthan K, Orr FW. Resorbing bone stimulates tumor cell growth. A role for the host microenvironment in bone metastasis. Am J Pathol. 1986;123:39–45
  36. Agha FP, Norman A, Hirschl S, Klein R. Paget’s disease coexistence with metastatic carcinoma. NY State J Med. 1976;76:734–735
  37. Powell N. Metastatic carcinoma in association with Paget’s disease of bone. Br J Radiol. 1983;56:582–585
  38. Krempien B. The Walker carcinosarcoma 256 as an experimental model of bone metastases; influence of local and metabolic factors on incidence and pattern of metastases. Calcif Tiss Int. 1984;36:S2
  39. Orr FW, Milar-Book W, Singh G. Chemotactic activity of bone and platelet TGFβ for bone metastasizing rat Walker carcinosarcoma cells. Invasion Metastasis. 1990;10:241–252
  40. Sasaki A, Alcalde RE, Nishiyama A, Lim DD, Mese H, Akedo H, et al. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption. Cancer Res. 1998;58:462–467
  41. Clohisy DR, Ramnaraine ML. Osteoclasts are required for bone tumors to grow and destroy bone. Orthop Res. 1998;16:660–666
  42. N Engl J Med. 1941;22:789–791
  43. Moseley JM, Kubota M, Dieffenbach-Jagger H, Wettenhall REH, Kemp BE, Suva LJ, et al. Parathyroid hormone-related protein purified from a human lung cancer cell line. Proc Natl Acad Sci USA. 1987;84:5048–5052
  44. Burtis WJ, Wu T, Bunch C, Wysolmerski JJ, Insogna KL, Weir EC, et al. Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protei from a tumor associated with humoral hyprcalcemia of malignancy. J Biol Chem. 1987;262:7151–7156
  45. Strewler GJ, Stern PH, Jacobs JW, Eveloff J, Klein RF, Leung SC, et al. Parathyroid hormone-like protein from renal carcinoma cells. Structural and functional homology with parathyroid hormone. J Clin Invest. 1987;80:1803–1807
  46. Suva LJ, Winslow GA, Wettenhall REH, Hammonds RG, Moseley JM, Dieffenbach-Jagger H, et al. A parathyroid hormone-related protein implicated in malignant hypercalcemia:cloning and expression. Science. 1987;237:893–896
  47. Rankin W, Grill V, Martin TJ. Parathyroid hormone-related protein and hypercalcemia. Cancer. 1997;15;:1564–1571
  48. Wysolmerski JJ, Broadus AE. Hypercalcemia of malignancy:thecentral role of parathyroid-hormone related protein. Annu Rev Med. 1994;45:189–200
  49. Guise TA. Parathyroid hormone-related protein and bone metastases. Cancer. 1997;15;:1572–1580
  50. Powell GJ, Southby J, Danks Ja, Stillwell RG, Hayman JA, Henderson MA, et al. Localization of parathyroid hormone-related protein in breast cancer metastases: Increased incidence in bone compared with other sites. Cancer Res. 1991;51:3059–3061
  51. Vargas SJ, Gillespie MT, Powell GJ, Southby J, Danks JA, Moseley JM, et al. Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridization. J Bone Miner Res. 1992;7:971–979
  52. Guise TA, Yin JJ, Taylor SD, Kumagai Y, Dallas M, Boyce BF, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest. 1996;98:1544–1549
  53. Yin JJ, Selander K, Chirgwin JM, Dallas M, Grubbs BG, Wieser R, et al. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 1999;103:197–206
  54. Birch MA, Carron JA, Scott M, Fraser WD, Gallagher JA. Parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor expression and mitogenic responses in human breast cancer cell lines. Br J Cancer. 1995;72:90–95
  55. Carron JA, Fraser WD, Gallagher JA. PTHrP and the PTH/PTHrP receptor are co-expressed in human breast and colon tumours. Br J Cancer. 1997;76:1088–1095
  56. Iezzoni JC, Bruns ME, Frierson HF, Scott MG, Pence RA, Deftos LJ, et al. Coexpression of parathyroid hormone-related protein and its receptor in breast carcinoma: A potential autocrine effector system. Mod Pathol. 1998;11:265–270
  57. Bundred NJ, Walker RA, Ratcliffe WA, Warwick J, Morrison JM, Ratcliffe JG. Parathyroid hormone related protein and skeletal morbidity in breast cancer. Eur J Cancer. 1992;28:690–692
  58. Onuma, E. Sato, K. Kaiho, S. Miura, M. Takahashi, S. Ogata, E. The role of PTHrP in malignancy-associated hypercalcemia and cachexia. Cancer-Induced Bone Diseases-Second International Conference 1999 (Abstract 23).
  59. Suda T, Udagawa N, Nakamura I, Miyaura C, Takahashi N. Modulation of osteoclast differentiation by local factors. Bone. 1995;17:87S–91S
  60. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Reviews. 1999;20:345–357
  61. Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/ RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun. 1999;256:449–455
  62. Matsuzaki K, Udagawa N, Takahashi N, Yamaguchi K, Yasuda H, Shima N, et al. Osteoclast differentiation factor (ODF) induces osteoclast-like cell formation in human peripheral blood mononuclear cell cultures. Biochem Biophys Res Commun. 1998;246:199–204
  63. Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Yano K, et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun. 1998;253:395–400
  64. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165–176
  65. Thomas RJ, Guise TA, Yin JJ, Elliot J, Horwood NJ, Martin TJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 1999;140:4451–4458
  66. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, et al. Reversion of the malignant phenotype of human breast cancer cells in three dimensional culture and in vivo by integrin blocking antibodies. J Cell Biol. 1997;137:231–245
  67. Kitazawa S, Maeda S. Development of skeletal metastases. Clin Ortop Rel Res. 1995;312:45–50
  68. Liapis H, Flath A, Kitazawa S. Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol. 1996;5:127–135
  69. Matsuura N, Puzon-McLaughlin W, Irie A, Morikawa Y, Kakudo K, Takada Y. Induction of experimental bone metastasis in mice by transfection of integrin alpha 4 beta 1 into tumor cells. Am J Pathol. 1996;148:55–61
  70. Price, J. T. Sharp, J. A. Thompson, E. W. In vitro response to bone sialoprotein (BSP) predicts bone metastatic potential of MDA-MB-231 human breast carcinoma cell subpopulations in nude mice. Cancer-Induced Bone Diseases-Second International Conference 1999 (Abstract 24).
  71. Gehron Robey P. The biochemistry of bone. Endocrinology and Metabolism Clinics of North America. 1989;18:859–902
  72. Grzesik WJ, Gehron Robey P. Bone matrix RGD glycoproteins: Immunolocalization and interaction with human primary osteoblastic bone cells in vitro. J Bone Miner Res. 1994;9:487–496
  73. Bianco P, Fisher LW, Young MF, Termine JD, Gehron Robey P. Expression of bone sialoprotein (BSP) in developing human tissues. Calcif Tissue Int. 1991;49:421–426
  74. Pierschbacher MD, Ruoslahti E. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature. 1984;309:30–33
  75. Seibel MJ, Woitge HW, Pecherstorfer M, Karmatschek M, Horn E, Ludwig H, et al. Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. Clin Endocrinol Metab. 1996;81:3289–3294
  76. Chen J, Shapiro HS, Sodek J. Developmental expression of bone sialoprotein mRNA in rat mineralized connective tissues. J Bone Miner Res. 1992;7:987–997
  77. Chenu C, Colucci S, Grano M, Zigrino P, Barattolo R, Zambonin G, et al. Osteocalcin induces chemotaxis, secretion of matrix proteins, and calcium-mediated intracellular signaling in human osteoclast-like cells. J Cell Biol. 1994;127:1149–1158
  78. Beresford JN, Joyner CJ, Devlin C, Triffit JT. The effects of dexamethasone and 1,25-dihydroxyvitamin D3 on osteogenic differentiation of human marrow stromal cells in vitro. Arch Oral Biol. 1994;39:941–947
  79. Reinholt FP, Hultenby K, Oldberg A, Heinegård D. Osteopontin- a possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA. 1990;87:4473–4475
  80. Oldberg A, Franzen A, Heinegård D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell binding sequence. Proc Natl Acad Sci USA. 1986;83:8819–8823
  81. Helfrich MH, Nesbitt SA, Dorey EL, Horton MA. Rat osteoclasts adhere to a wide range of RGD (Arg-Gly-Asp) peptide-containing proteins, including the bone sialoproteins and fibronectin, via a beta 3 integrin. J Bone Miner Res. 1992;7:335–343
  82. Davies J, Warwick J, Totty N, Philip R, Helfrich M, Horton M. The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor. J Cell Biol. 1989;109:1817–1826
  83. Ross FP, Chappel J, Alvarez JI, Sander D, Butler WT, Farach-Carson MC, et al. Interactions between bone matrix proteins osteopontin and bone sialoprotein and the osteoclast integrin alpha v beta 3 potentiate bone resorption. J Biol Chem. 1993;268:9901–9907
  84. van der Pluijm G, Mouthaan H, Baas C, de Groot H, Papapoulos S, Löwik C. Integrins and osteoclastic resorption in three bone organ cultures: differential sensitivity to synthetic Arg-Gly-Asp peptides during osteoclasts formation. J Bone Miner Res. 1994;9:1021–1028
  85. Koukoulis GK, Virtanen I, Korhonen M, Laitinen L, Quaranta V, Gould VE. Immunohistochemical localization of integrins in normal, hyperplastic, and neoplastic breast. Am J Pathol. 1991;139:787–799
  86. Pignatelli M, Cardillo MR, Hanby A, Stamp GW. Integrins and their accessory adhesion molecules in mammary carcinomas: Loss of polarization in poorly differentiated tumors. Hum Pathol. 1992;23:1159–1166
  87. van der Pluijm G, Vloedgraven H, Papapoulos S, Lowik C, Grezesik W, Kerr J, et al. Attachment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components. Lab Invest. 1997;77:665–675
  88. van der Pluijm G, Vloedgraven HJM, Ivanov B, Robey FA, Grzesik WJ, Gehron WJ, et al. Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone. Cancer Res. 1996;56:1948–1955
  89. Sung V, Stubbs JT, Fisher L, Aaron AD, Thompson EW. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins. J Cell Physiol. 1998;176:482–494
  90. Bellahcène A, Merville M, Castronovo V. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res. 1994;54:2823–2826
  91. Bellahcene A, Kroll M, Liebens F, Castronovo V. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development. J Bone Miner Res. 1996;11:665–670
  92. Bellahcene A, Antoine N, Clausse N, Tagliabue E, Fisher LW, Kerr JM, et al. Detection of bone sialoprotein in human breast cancer tissue and cell lines at both protein and messenger ribonucleic acid levels. Lab Invest. 1996;75:203–210
  93. Bellahcene A, Menard S, Bufalino R, Moreau L, Castronovo V. Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer. 1996;69:350–353
  94. Gillespie MT, Thomas RJ, Pu ZY, Zhou H, Martin TJ, Findlay DM. Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers. Int J Cancer. 1997;73:812–815
  95. Diel, I. J. Solomayer, E. F. Pfeilschifter, J. Seibel, M. J. Gollan, Ch, Conradi, R. Maisenbacher, H. Naser, W. Hoyle, N. Bastert, G. Serum bone sialoprotein and crosslaps are both highly predictive for bone metastases in breast cancer. Cancer-Induced Bone Diseases-Second International Conference 1999 (Abstract 36).
  96. Benaud C, Dickson RB, Thompson EW. Roles of the matrix metalloproteinases in mammary gland development and cancer. Breast Cancer Res Treat. 1998;50:97–116
  97. Lochter A, Bissell MJ. An odyssey from breast to bone:Multi-step control of mammary metatases and osteolysis by matrix metalloproteinases. APMIS. 1999;107:128–136
  98. Foucré D, Bouchet C, Pourreau-Scheider N, Gentile A, Martin PM, Desplaces A, et al. Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. Br J Cancer. 1991;64:926–932
  99. Cockett MI, Murphy G, Birch ML, O’Connell JP, Crabbe T, Millican AT, et al. Matrix metalloproteinases and metastatic cancer. Biochem Soc Symp. 1998;63:295–313
  100. Kurizaki T, Toi M, Tominaga T. Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma. Oncol Rep. 1998;5:673–677
  101. Andreasen PA, Kjøller L, Christensen L. The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer. 1997;72:1–22
  102. Rochefort H, Liaudet-Coopman E. Cathepsin D in cancer metastasis: A protease and a ligand. APMIS. 1999;107:86–95
  103. Duffy MJ, Reilly D, O’Sullivan C, O’Higgins N, Fennelly JJ, Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res. 1990;50:6827–6829
  104. Gaffney PJ, Cooke DA, Burnand KG. Urokinase and its receptor: Marker of malignancy?. Adv Exp Med Biol. 1994;360:187–191
  105. Grondahl-Hansen J, Hilsenbeck SG, Christensen IJ, Clark GM, Osborne CK, Brunner N. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat. 1997;43:153–163
  106. Duffy MJ, Duggan C, Maguire T, Mulcahy K, Elvin P, McDermott E, et al. Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer. Enzyme Protein. 1996;49:85–93
  107. Duffy MJ, Reilly D, O’Sullivan C, O’Higgins N, Fennelly JJ, Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res. 1990;50:6827–6829
  108. Duggan C, Kennedy S, Kramer MD, Barnes C, Elvin P, McDermott E, et al. Plasminogen activator inhibitor type 2 in breast cancer. Br J Cancer. 1997;76:622–627
  109. Reilly D, Andreasen P, Duffy MJ. Studies on plasminogen activator inhibitor 1 levels in human breast cancer. Biochem Soc Trans. 1990;18:354–355
  110. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest. 1997;100:58–67
  111. Werb Z. ECM and cell surface proteolysis:regulating cellular ecology. Cell. 1997;91:439–442
  112. Grondahl-Hansen J, Peters HA, van Putten WLJ, Look MP, Pappot H, Ronne E, et al. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res. 1995;1:1079–1087
  113. Bohuslav J, Horejsi V, Hansmann C, Stockl J, Weidle UH, Majdic O, et al. Urokinase plasminogen activator receptor, beta 2-integrins, and Src-kinases within a single receptor complex of human monocytes. J Exp Med. 1995;181:1381–1390
  114. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, et al. Regulation of integrin function by the urokinase receptor. Science. 1996;273:1551–1555
  115. Xue W, Mizukami I, Todd RF, Petty HR. Urokinase-type plasminogen activator receptors associate with betal and beta3 integrins of fibrosarcoma cells: Dependence on extracellular matrix components. Cancer Res. 1997;57:1682–1689
  116. Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, et al. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with alpha v beta 3. Cell. 1996;85:683–693
  117. Bourguignon LY, Gunja-Smith Z, Iida N, Zhu HB, Young LJ, Muller WJ, et al. CD44v(3,8–10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol. 1998;176:206–215
  118. Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev. 1999;13:35–48
  119. Littlewood-Evans A, Bilbe G, Bowler WB, Farley D, Wlodarski B, Kokubo T, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 1997;57:5386–5390
  120. Ohishi K, Fujita N, Morinaga Y, Tsuruo T. H-31 human breast cancer cells stimulate type I collagenase production in osteoblast-like cells and induce bone resorption. Clin Exp Metastasis. 1995;13:287–295
  121. Polette M, Gilles C, Marchand V, Seiki M, Tournier JM, Birembaut P. Induction of membrane-type matrix metalloproteinase 1 (MT1-MMP) expression in human fibroblasts by breast adenocarcinoma cells. Clin Exp Metastasis. 1997;15:157–163
  122. Danø K, Rømer J, Nielsn BS, Bjørn S, Pyke C, Rygaard J, et al. Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. APMIS. 1999;107:120–127
  123. Thompson EW, Yu M, Bueno J, Jin L, Maiti SN, Palao-Marco FL, et al. Collagen induced MMP-2 activation in human breast cancer. Breast Cancer Res Treat. 1994;31:357–370
  124. Gilles C, Polette M, Seiki H, Birembaut P, Thompson EW. Implication of collagen type I-induced matrix metalloproteinase expression and matrix metalloproteinase-2 activation in metastatic progression of breast carcinoma. Lab Inv. 1997;76:651–660
  125. Gilles C, Bassuk JA, Pulyaeva H, Sage EH, Foidart JM, Thompson EW. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res. 1998;58:5529–5536
  126. Farina AR, Coppa A, Tiberio A, Tacconelli A, Turco A, Colletta G, et al. Transforming growth factor-betal enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity. Int J Cancer. 1998;75:721–730
  127. Yoneda T, Sasaki A, Dunstan C, williams PJ, Bauss F, De Clerck YA, et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest. 1997;99:2509–2517
  128. Wang M, Liu YE, Greene J, Sheng S, Fuchs A, Rosen EM, et al. Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene. 1997;14:2767–2774
  129. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst. 1989;82:4–6
  130. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27–31
  131. Holmgren L, O’Reilley MS, Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1:149–153
  132. Hanahan D, Folkman J. Patterns and emerging mechanisms of angiogenic switch during tumorigenesis. Cell. 1996;86:353–364
  133. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333:1757–1763
  134. Weidner N, Semple P, Welch W, Folkman J. Tumor angiogenesis and metastases-Correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1–6
  135. Wakui S, Furusato M, Sasaki H, Akiyama A, Kinoshito I, Asano K, et al. Tumor angiogenesis in prostatic carcinoma with and without bone metastasis; a morphometric study. J Pathol. 1992;168:257–262
  136. Chodak GW, Haudenschild C, Gittes RF, Folkman J. Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder. Ann Surg. 1980;192:762–771
  137. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularization to metastasis of non-small lung carcinoma. Lancet. 1992;340:145–146
  138. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, et al. Breast carcinoma: Vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res. 1999;59:856–861
  139. Goede V, Fleckenstein G, Dietrich M, Osmers RG, Kuhn W, Augustin HG. Prognostic value of angiogenesis in mammary tumors. AntiCancer Res. 1998;18:2002–2199
  140. Toi M, Inada K, Suzuki H, Tominaga T. Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat. 1995;36:193–204
  141. Heimann R, Ferguson D, Gray S, Hellman S. Assessment of intratumoral vascularization (angiogenesis) in breast cancer prognosis. Breast Cancer Res Treat. 1998;52:147–158
  142. Locopo N, Fanelli M, Gasparini G. Clinical significance of angiogenic factors in breast cancer. Breast Cancer Res Treat. 1998;52:159–173
  143. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocrine Rev. 1997;18:4–25
  144. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial groath factor (VEGF) and its receptors. FASEB. 1999;13:9–22
  145. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability and angiogenesis. Am J Pathol. 1995;146:1029–1039
  146. Pepper MS, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Comm. 1991;181:902–906
  147. Unemori EN, Ferrara N, Bauer EA, Amento EP. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol. 1992;153:557–562
  148. Watanabe Y, Lee SW, Detmar M, Ajioka I, Dvorak HF. Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal endothelial cells. Oncogene. 1997;14:2025–2032
  149. Poltorak Z, Chen T, Sivan R, Kandelis Y, Spira G, Vlodavsky I, et al. VEGF145:a secreted VEGF form that binds to extracellular matrix. J Biol Chem. 1997;272:7151–7158
  150. Jakeman LB, Winer J, Bennet GL, Altar CA, Ferrara N. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest. 1992;89:244–253
  151. de Vries C, Escobedo JA, Ueno H, Houck KA, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 1992;255:989–991
  152. Quinn T, Peters KG, de Vries C, Ferrara N, Williams LT. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA. 1993;90:7533–7537
  153. Olofsson B, Pajusola K, Kaipaineen A, VonEuler G, Joukov V, Sakserla O, et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc Natl Acad Sci USA. 1996;93:2576–2581
  154. Olofsson B, Korpelainen E, Mandriota S, Pepper MS, Aase K, Kumar V, et al. VEGF-B binds to V. E. G. F. R-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA. 1998;95:11709–11714
  155. Joukov V, Pajusola K, Kaipainen A, Chilov D, lathinen I, Kukk E, et al. A novel vascular endothelial growth factor, VEGF-C is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996;15:290–298
  156. Achen MG, Jeltsch M, Kukk E, Makinen T, Vitali A, Wilks AF, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA. 1998;95:548–553
  157. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16:4604–4613
  158. Mazure NM, Chen EY, Yeh P, Laderout KR, Giaccia AJ. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res. 1996;56:3436–3440
  159. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Sasazuki T, Kerbel RS. Mutant ras oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995;55:4575–4580
  160. Brown LF, Berse B, Jackman RW, Tognazzi K, Manseau EJ, Dvorak HF, et al. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol. 1993;143:1255–1262
  161. Plate KH, Breier G, Millauer B, Ullrich A, Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res. 1993;53:5822–5827
  162. Kim KJ, Li B, Winer J, Armanini M, Gillet N, Philips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature. 1993;362:841–844
  163. Warren RS, Yuan H, Matli MR, Gillett Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest. 1995;95:1789–1797
  164. Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig N. Halting angiogenesis suppresses carcinoma cell invasion. Nature Med. 1997;3:1222–1227
  165. Davis S, Aldrich TH, Jones Acheson A, Compton DL, Jain V, Ryan TE, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996;87:1161–1169
  166. Maisonpierre PC, Jones PF, Wiegand SJ, Radziejewski C, Compton D, Aldrich TH, et al. Angiopoietin-2: A natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science. 1997;277:55–60
  167. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999;284:1994–1998
  168. Brooks PC, Montgomery AMP, Rosenfeld M, Reisfeld R, Hu T, Klier G, et al. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogeneic bloodvessels. Cell. 1994;749:1157–1164
  169. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh D. Definition of two angiogenic pathways by distinct αv integrins. Science. 1995;270:1500–1502
  170. Eliceiri BP, Cheresh DA. The role of αv integrins during angiogenesis. Mol Medicine. 1998;4:741–750
  171. Yu AE, Hewitt RE, Connor EW, Stetler-Stevenson WG. Matrix Metalloproteinases-Novel targets for directed cancer therapy. Drugs & Aging. 1997;11:229–244
  172. Moses MA. Regulation of neovascularization by matrix metalloproteinases and their inhibitors. Stem Cells. 1997;15:180–189
  173. Folkman J, Ingber D. Inhibition of angiogenesis. Cancer Biol. 1992;3:89–96
  174. O’Reilly MS, Holmgren L, Chen CC. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 1996;2:689–692
  175. O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277–285
  176. Boehm T, Folkman J, Browder T, O’Reilly MS. Anti-angiogenic therapy of experimental cancer does not induce aquired drug resistance. Nature. 1997;390:404–407
  177. Muragaki Y, Timmons S, Griffith CM, Oh SP, Fadel B, Quertermous T, et al. Mouse Coll8a1 is expresed in atissue specific manner as three alternative variants and is localized in basement membrane zones. Proc Natl Acad Sci USA. 1995;92:8763–8767
  178. Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J. 1999;18:4414–4423
  179. Paterson AHG. The emerging role of bisphosphonates in the prevention of bone metastases. TEM. 1999;10:24–29

☆ Address all correspondence to: Dr. Gabri van der Pluijm, Leiden University Medical Center (LUMC), Department of Endocrinology & Metabolic Diseases C4-R, Albinusdreef 2, 2333 ZA Leiden, the Netherlands.

PII: S0305-7372(99)90143-3

doi: 10.1053/ctrv.1999.0143

Cancer Treatment Reviews
Volume 26, Issue 1 , Pages 11-27 , February 2000

Article Tools